Biomarkers in chronic kidney disease: a review.

Renal Research, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Kidney International (Impact Factor: 8.52). 06/2011; 80(8):806-21. DOI: 10.1038/ki.2011.198
Source: PubMed

ABSTRACT Chronic kidney disease (CKD) is a major public health problem. The classification of CKD by KDOQI and KDIGO and the routine eGFR reporting have resulted in increased identification of CKD. It is important to be able to identify those at high risk of CKD progression and its associated cardiovascular disease (CVD). Proteinuria is the most sensitive marker of CKD progression in clinical practice, especially when combined with eGFR, but these have limitations. Hence, early, more sensitive, biomarkers are required. Recently, promising biomarkers have been identified for CKD progression and its associated CVD morbidity and mortality. These may be more sensitive biomarkers of kidney function, the underlying pathophysiological processes, and/or cardiovascular risk. Although there are some common pathways to CKD progression, there are many primary causes, each with its own specific pathophysiological mechanism. Hence, a panel measuring multiple biomarkers including disease-specific biomarkers may be required. Large, longitudinal observational studies are needed to validate candidate biomarkers in a broad range of populations prior to implementation into routine CKD management. Recent renal biomarkers discovered include neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, and liver-type fatty acid-binding protein. Although none are ready for use in clinical practice, it is timely to review the role of such biomarkers in predicting CKD progression and/or CVD risk in CKD.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The present study investigated the protective effect of extracts prepared from grape, coriander, roselle and fennel in a rat model of kidney dysfunction induced by intraperitoneal cisplatin. A mixture of ethanol and petroleum ether extracts was prepared from a given plant. Six groups of rats were analyzed; control healthy, cisplatin group and 4 test groups where rats were given a daily oral dose of each extract mixture before cisplatin injection. Different biochemical and cytogenetic parameters and kidney histopathology were determined. Total phenolic contents, fatty acids and unsaponifiable matter (UNSAP) were assessed in the extracts. Results showed roselle ethanol extract to have the highest phenolic content (15.584 g GAE/100 g extract). Fatty acid analysis revealed the presence of linoleic and linolenic acid in all studied plants. Coriander oil showed the highest content of unsaturated fatty acids (85%). GLC investigation of the UNSAP showed the presence of campesterol in all the studied plants. Grape oil contained the highest content of phytosterol (15.9%). Cisplatin treatment induced significant increase in plasma urea, creatinine and malondialdehyde along with significant reduction in plasma albumin, total protein, catalase activity and total antioxidant level as well as reduction in creatinine clearance compared to normal control. Histopathological examination proved the induction of kidney dysfunction by cisplatin. Chromosomal aberration and sperm-shape abnormalities were noticed after cisplatin treatment. Administration of extract mixtures produced improvements in biochemical, histopathological and cytogenetic parameters. Extracts mixture under study offered protection from cisplatin induced kidney dysfunction via antioxidant and possibly anti-inflammatory actions.
    Polish Journal of Food and Nutrition Sciences 03/2014; 64(1):49-57.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: mRNA for biomarkers of kidney injury extracted from urinary exosomes may reflect or predict levels of the corresponding protein after transplantation and clinical outcomes.
    PLoS ONE 01/2014; 9(6):e98644. · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Urinary exosomes and microvesicles (EMV) are promising biomarkers for renal diseases. Although the density of EMV is very low in urine, large quantity of urine can be easily obtained. In order to analyze urinary EMV mRNA, a unique filter device to adsorb urinary EMV from 10 mL urine was developed, which is far more convenient than the standard ultracentrifugation protocol. The filter part of the device is detachable and aligned to a 96-well microplate format, therefore multiple samples can be processed simultaneously in a high throughput manner following the isolation step. For EMV mRNA quantification, the EMV on the filter is lysed directly by adding lysis buffer and transferred to an oligo(dT)-immobilized microplate for mRNA isolation followed by cDNA synthesis and real-time PCR. Under the optimized assay condition, our method provided comparable or even superior results to the standard ultracentrifugation method in terms of mRNA assay sensitivity, linearity, intra-assay reproducibility, and ease of use. The assay system was applied to quantification of kidney-specific mRNAs such as NPHN and PDCN (glomerular filtration), SLC12A1 (tubular absorption), UMOD and ALB (tubular secretion), and AQP2 (collecting duct water absorption). 12-hour urine samples were collected from four healthy subjects for two weeks, and day-to-day and individual-to-individual variations were investigated. Kidney-specific genes as well as control genes (GAPDH, ACTB, etc.) were successfully detected and confirmed their stable expressions through the two-week study period. In conclusion, this method is readily available to clinical studies of kidney diseases.
    PLoS ONE 01/2014; 9(10):e109074. · 3.53 Impact Factor


Available from
May 31, 2014